These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 18637152

  • 1. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P, Sánchez C, Contreras HR, Vergara J, Acevedo C, Cabezas J, Huidobro C, Noé G, Castellón EA.
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [Abstract] [Full Text] [Related]

  • 2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 3. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT, Le H, McFann KK, Blackman MR.
    Am J Physiol Endocrinol Metab; 2005 Mar 01; 288(3):E573-84. PubMed ID: 15536203
    [Abstract] [Full Text] [Related]

  • 5. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
    Hsieh JT, Chen SC, Yu HJ, Chang HC.
    Prostate; 2011 Jul 01; 71(10):1115-21. PubMed ID: 21557276
    [Abstract] [Full Text] [Related]

  • 6. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997 Jul 01; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 7. Androgen and prostatic stroma.
    Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G.
    Asian J Androl; 2003 Mar 01; 5(1):19-26. PubMed ID: 12646998
    [Abstract] [Full Text] [Related]

  • 8. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C, Varela C, Correia-da-Silva G, Tavares da Silva E, Carvalho RA, Costa SC, Cunha SC, Fernandes JO, Teixeira N, Roleira FM.
    Biochimie; 2013 Nov 01; 95(11):2097-106. PubMed ID: 23933094
    [Abstract] [Full Text] [Related]

  • 9. The antigonadotropic action of testosterone but not 7alpha-methyl-19-nortestosterone is attenuated through the 5alpha-reductase pathway in the castrated male rat pituitary gland.
    Bandivdekar AH, Karp R, Sundaram K, Kumar N.
    J Androl; 2000 Nov 01; 21(2):268-75. PubMed ID: 10714822
    [Abstract] [Full Text] [Related]

  • 10. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
    Boudon C, Lobaccaro JM, Lumbroso S, Lechevallier E, Mottet N, Gibelin B, Sultan C.
    Cell Mol Biol (Noisy-le-grand); 1995 Dec 01; 41(8):1007-15. PubMed ID: 8747081
    [Abstract] [Full Text] [Related]

  • 11. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 01; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 12. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J.
    J Clin Endocrinol Metab; 1990 Dec 01; 71(6):1552-5. PubMed ID: 1699965
    [Abstract] [Full Text] [Related]

  • 13. The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.
    Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, Till B, Gropp D, Semon A, Reel JR.
    J Steroid Biochem Mol Biol; 2010 Oct 01; 122(4):212-8. PubMed ID: 20599615
    [Abstract] [Full Text] [Related]

  • 14. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M, Bartsch W, Thomsen M, Voigt KD.
    J Steroid Biochem; 1983 Jul 01; 19(1A):155-61. PubMed ID: 6193338
    [Abstract] [Full Text] [Related]

  • 15. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
    Justulin LA, Acquaro C, Carvalho RF, Silva MD, Felisbino SL.
    Int J Androl; 2010 Jun 01; 33(3):489-99. PubMed ID: 19490185
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of men on finasteride.
    Gormley GJ.
    Semin Urol Oncol; 1996 Aug 01; 14(3):139-44. PubMed ID: 8865475
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.